Posaproca/SPCG

Antiandrogen followed by TAB on biochemical progression versus TAB

Integer posuere erat a ante venenatis dapibus posuere velit aliquet. Aenean eu leo quam. Pellentesque ornare sem lacinia quam venenatis vestibulum. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit tempus porttitor.

Finished

Posaproca/SPCG info

Principal investigator

Jonas Hugosson

Contact details

Patients

Tx,Nx,Gx,M1

Treatment

Leuprolide flutamide 250 mg x 3 (A) versus flutamide 250 mg x 3 (B) follow on progression by withdrawal of flutamide (A) and leuprolide (B)

Inclusion period

1992 - 311203

Number of patients

468

Sponsor

OrionPharma and Schering Plough

Antiandrogen followed by TAB on biochemical progression versus TAB

Posaproca/SPCG info

More trials

SPCG 19/ Get-Randomized- Prostate (Grand-P): A randomized, multi-center trial of immediate curative therapy compared with standard conservative treatment in older men aged ≥ 75 years with non-metastatic, high-risk prostate cancer

Prostate Cancer Active Surveillance Trigger Trial (PCASTT)

No information available

Primary radical prostatectomy versus primary radiotherapy for locally advanced prostate cancer: an open randomized clinical trial

A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation ± Docetaxel for Non-metastastic Prostate Cancer Patients with a Rising PSA

A Randomized phase III trial of six cycles of docetaxel versus surveillance plus hormonal treatment after radical radiotherapy in patients with intermediate or high-risk prostate cancer (SPCG-13 AdRad)

An open randomised phase III trial of six cycles of docetaxel versus surveillance after radical prostatectomy in prostate cancer patients with high grade pT3 or margin positive pT2

Randomised trial comparing radical prostatectomy versus radiotherapy plus protocol on follow-up of non-randomised patients with localised prostate cancer

An open pilot study evaluating intermittent androgen suppression in patients with advanced prostate cancer

Institution of second-line Estracyt therapy at an increase in PSA values for metastatic prostate cancer

Post-treatment Prostatic Biopsies after Antiandrogen treatment with or without Radiotherapy

Randomized trial of locally advanced prostate cancer. Antiandrogen treatment with or without radiotherapy

A randomized, double-blind, parallel-group trial comparing Casodex 150 mg once daily with placebo in patients with non-metastatic prostate cancer

High-dose Polyestradiol Phosphate versus Total Androgen Blockade

Expectation or radical prostatectomy on early prostate cancer

Cancelled trial due to Socialstyrelsen in Sweden

Orchiectomy plus placebo versus orchiectomy plus cyproteronacetat

Comparison of Estramustine Phosphate to Stilbestrol in the treatment of G3 M Prostatic